Skye Bioscience, Inc.
SKYE · XNASCIK 1516551fmd_11HGJVBXZW4PMA8YW9HJZ0NRSHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Nov 01, 2011 to Jun 30, 2026, 61 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 1 | 0 | 0 | 2 | 2 | 3 | 6 | 6 | 19 | 42 |
| Total operating expenses | 4 | 4 | 5 | 7 | 6 | 8 | 18 | 35 | 30 | 58 |
| Operating income | (4) | (4) | (5) | (7) | (6) | (8) | (18) | (35) | (30) | (58) |
| Interest expense | – | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Interest and investment income | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 |
| Other non-operating income (expense) | – | – | (15) | 8 | (0) | (1) | (1) | (3) | 4 | 2 |
| Income before taxes | (3) | (3) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (3) | (3) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) |
| Net income | (3) | (3) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) |
| Net income to common shareholders | (4) | (4) | (19) | 1 | (7) | (9) | (19) | (38) | (27) | (56) |